MediciNova, Inc.
Combination of ibudilast and riluzole and methods of using same
Last updated:
Abstract:
The present disclosure relates generally to methods for treating neurodegenerative diseases, including their progressive forms. In particular, the present disclosure pertains to methods of treating or preventing neurodegenerative diseases, including their progressive forms and their associated symptoms by administering a combination of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) and riluzole, or pharmaceutically acceptable salts of one or both thereof.
Status:
Grant
Type:
Utility
Filling date:
18 Jun 2020
Issue date:
22 Mar 2022